Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for ELISA-Based Screening of Clones – V 2.0

Posted on By


Biosimilars: SOP for ELISA-Based Screening of Clones – V 2.0


Standard Operating Procedure for ELISA-Based Screening of Clones in Biosimilar R&D

Department Biosimilars
SOP No. SOP/BS/013/2025
Supersedes SOP/BS/013/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a standardized method for using Enzyme-Linked Immunosorbent Assay (ELISA) to screen biosimilar-producing cell clones based on protein expression levels in the culture supernatant.

2. Scope

This SOP applies to biosimilar research and development laboratories using ELISA-based assays to select high-expressing clones during early-phase clone screening.

3. Responsibilities

  • Research Associate: Prepares samples, standards, and performs ELISA procedures.
  • Lab Technician: Assists in plate preparation, reagent handling, and recordkeeping.
  • QA Representative: Ensures compliance of assay data and documentation standards.

See also  Biosimilars: SOP for Vector Design and Cloning - V 2.0

4. Accountability

The Head of Analytical Development is accountable for the implementation and validation of the ELISA procedure for clone screening purposes.

5. Procedure

5.1 Materials and Reagents

  • Pre-coated ELISA 96-well plates or uncoated plates with capture antibody
  • Standards and controls (known concentration of biosimilar protein)
  • Culture supernatants from clones
  • Detection antibody (biotinylated or HRP-conjugated)
  • Substrate solution (TMB)
  • Stop solution (e.g., 2N H2SO4)
  • Wash buffer (PBS-Tween 20)
  • Plate washer or multichannel pipette
  • Microplate reader

5.2 Sample Preparation

  1. Collect culture supernatants after 48–72 hours of clone growth.
  2. Centrifuge at 3000 rpm for 10 minutes to remove cell debris.
  3. Store aliquots at -20°C if not used immediately.

5.3 Assay Setup

  1. Add 100 µL of standards, controls, and samples in duplicates to the plate.
  2. Incubate for 1–2 hours at room temperature or as per kit instructions.
  3. Wash plate 3–5 times with PBS-Tween using plate washer or manually.
  4. Add 100 µL of detection antibody to each well and incubate again as directed.
  5. Repeat washing step, then add 100 µL TMB substrate and incubate in dark.
  6. Stop reaction after color development using 100 µL stop solution.
  7. Read absorbance at 450 nm using a microplate reader.
See also  Biosimilars: SOP for Southern Blot Analysis - V 2.0

5.4 Data Analysis

  1. Generate standard curve from absorbance readings of known standards.
  2. Calculate protein concentrations in each clone sample using curve-fit equations.
  3. Record expression levels in the ELISA Clone Screening Log (Annexure-1).

5.5 Result Interpretation and Documentation

  1. Mark clones with expression ≥80% of control as “Positive.”
  2. Verify plate layout, sample positions, and replicate consistency.
  3. Review assay with QA before shortlisting clones.

6. Abbreviations

  • ELISA: Enzyme-Linked Immunosorbent Assay
  • HRP: Horseradish Peroxidase
  • TMB: Tetramethylbenzidine
  • PBS: Phosphate Buffered Saline

7. Documents

  1. ELISA Clone Screening Log (Annexure-1)
  2. Standard Curve Record Sheet (Annexure-2)

See also  Biosimilars: SOP for Productivity Testing in Small-Scale Cultures - V 2.0

8. References

  • ICH Q6B – Specifications: Test Procedures and Acceptance Criteria for Biotech Products
  • WHO Guidelines on Quality Control of Biotherapeutics
  • CDSCO Biologics Assay Guidelines

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: ELISA Clone Screening Log

Date Clone ID Sample Type Absorbance (450 nm) Expression Level (ng/mL) Result Operator
03/05/2025 CL-013 Supernatant 1.238 96.5 Positive Rajesh Kumar

Annexure-2: Standard Curve Record Sheet

Standard (ng/mL) Absorbance (450 nm)
0 0.032
10 0.210
25 0.456
50 0.782
100 1.295
200 1.890

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added curve log annexure and standard interpretation Annual SOP update
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: BA-BE Studies: SOP for First-Aid Management of Mild Reactions – V 2.0
Next Post: API Manufacturing: SOP for Distillation and Purification of Recovered Solvents – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version